Verastem

VSTM

Market cap $504M

Verastem (VSTM) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced the grant of 399,750 restricted stock units to 30 new employees and the grant of stock options to purchase 91,000 shares of its common stock to one new employee. The awards were granted pursuant to the Nasdaq inducement grant exception as an inducement material to the employee's acceptance of employment wit.

Verastem, Inc. (VSTM) Discusses Preliminary TARGET-D 101 Data for VS-7375 in KRAS G12D Mutated Cancers Transcript

BOSTON--(BUSINESS WIRE)---- $VSTM #CRC--VS-7375 (investigational KRAS G12D ON/OFF inhibitor) demonstrates clinical activity with a favorable safety profile in TARGET-D 101 clinical trial.

Verastem, Inc. is maintained at a Buy rating, driven by upcoming clinical catalysts and positive early-stage data in KRAS G12D mutant solid tumors. VSTM expects key data readouts from the TARGET-D 101 phase 1/2 study in 2026 and is advancing three phase 2 registration-directed studies for PDAC, NSCLC, and CRC for VS-7375. Positive phase 1b/2a RAMP 205 results in 1st-line metastatic PDAC (86% OS at 6 months, 52% cORR) support further development of avutometinib/defactinib combinations.

Verastem, Inc. (NASDAQ:VSTM) stock is trading higher on Wednesday as the company announced positive updated results from its RAMP 205 trial, which evaluates the efficacy of its drug combination in treating metastatic pancreatic cancer.

BOSTON--(BUSINESS WIRE)---- $VSTM #CancerResearch--Verastem Oncology announces updated results from RAMP 205 clinical trial in first-line metastatic pancreatic ductal adenocarcinoma.

BOSTON--(BUSINESS WIRE)---- $VSTM #CRC--Verastem doses first patient in TARGET-D 201, a registration-directed Phase 2 trial of VS-7375 in KRAS G12D-mutated advanced pancreatic cancer.

BOSTON--(BUSINESS WIRE)---- $VSTM #CRC--Verastem Oncology to report progress across the VS-7375 oral KRAS G12D (ON/OFF) TARGET-D program and updated Phase 1/2 TARGET-D 101 data.

BOSTON--(BUSINESS WIRE)---- $VSTM #CRC--FDA grants Fast Track designation to VS-7375, an oral investigational KRAS G12D inhibitor, for locally advanced or metastatic KRAS G12D-mutated NSCLC.